26 patents
Page 2 of 2
Utility
Anti-CD40 antibodies
2 Mar 20
The invention provides an antibody or fragment thereof that specifically binds to human CD40.
Peter Ellmark, Karin Enell Smith, Niina Veitonmaki
Filed: 17 Dec 14
Utility
Bispecific Antibody Against OX40 and CTLA-4
12 Feb 20
The present invention provides bispecific polypeptides, such as bispecific antibodies, comprising a first binding domain capable of specifically binding to OX40, and a second binding domain capable of specifically binding to CTLA-4.
Peter Ellmark, Christina Furebring, Per Norlen, Niina Veitonmaki
Filed: 30 Apr 18
Utility
Oncofetal Antigen Binding Proteins and Related Compositions and Methods
18 Dec 19
The present disclosure relates to protein molecules that specifically bind to 5T4 and/or 4-1BB.
David Bienvenue, Gabriela Hernandez-Hoyos, Lynda Misher, Danielle Mitchell, Peter Ellmark, Anna Sall, Christina Furebring, Laura von Schantz, Sara Fritzell, Laura Varas
Filed: 20 Feb 19
Utility
Novel Anti-CD137 Antibodies and Uses Thereof
20 Nov 19
The present invention relates to antibodies (and fragments, variants, fusions and derivatives thereof) with binding specificity for domain 2 of human CD137 which are capable of inhibiting the binding of a reference antibody to human CD137.
Peter Ellmark, Sara Fritzell, Christina Furebring, Jessica Petersson, Anna Sall, Karin Enell Smith, Laura Varas, Laura Von Schantz, Niina Veitonmaki
Filed: 20 Nov 17
Utility
Novel ANTI-CD137 Antibodies and Uses Thereof
20 Nov 19
The present invention relates to antibodies (and fragments, variants, fusions and derivatives thereof) with binding specificity for domain 2 of human CD137 which are capable of inhibiting the binding of a reference antibody to human CD137.
Peter Ellmark, Sara Fritzell, Christina Furebring, Jessica Petersson, Anna Sall, Karin Enell Smith, Laura Varas, Laura Von Schantz, Niina Veitonmaki
Filed: 16 Jul 19
Utility
Bispecific Polypeptides to GITR and CTLA-4
9 Oct 19
The present invention provides multispecific polypeptides, such as bispecific antibodies, comprising a first binding domain capable of specifically binding to GITR, and a second binding domain capable of specifically binding to CTLA-4.
Peter Ellmark, Sara Fritzell, Christina Furebring, Anne Kvarnhammar, Mattias Levin, Per Norlen, Eva Nyblom, Niina Veitonmaki, Magnus Winnerstam
Filed: 20 Nov 17